Franse LV, Di Bari M, Shorr RI, Resnick HE, van Eijk JTM, Bauer DC, Newman AB, Pahor M, for the Health, Aging, and Body Composition Study Group: Type 2 diabetes in older well-functioning people: who is undiagnosed? Data from the Health, Aging, and Body Composition Study. Diabetes Care 24:2065–2070, 2001
In the first sentence under conclusions on page 2067, “one-third of all older individuals” should read “one-third of all older individuals with diabetes.” The paragraph containing the correct sentence is shown here:
The present study shows that about one-third of all older individuals with diabetes remain undiagnosed. In this study of healthier older adults, men, those with a history of hypertension, and those with high BMI and large waist circumference were at the highest risk of having undiagnosed diabetes. Screening for diabetes may be more efficient among these subgroups, especially among individuals with combinations of these risk factors, in which the NNTS [number needed to screen] to identify one undiagnosed diabetic individual was lowest.
Rolka DB, Venkat Narayan KM, Thompson TJ, Goldman D, Lindenmayer J, Alich K, Bacall D, Benjamin EM, Lamb B, Stuart DO, Engelgau MM: Performance of recommended screening tests for undiagnosed diabetes and dysglycemia. Diabetes Care 24:1899–1903, 2001
In the first complete sentence on page 1903, “336 ÷ (336 + 552) = 29.8%” should read “336 ÷ (336 + 552) = 37.8%.” The sentence containing the correct calculation is shown here:
The projected positive predictive value (proportion of actual cases among those who have positive tests) would be 336 ÷ (336 + 552) = 37.8%.
Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, Takahashi A, Sugimura K, Koike Y, Ishii J, Sakamoto N, the SNK-860 Diabetic Neuropathy Study Group: Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 24:1776–1782, 2001
In Table 2 on page 1779 of the above article, the units of measure under the row headings “F wave minimum latency in median” and “F wave minimum latency in tibial” were listed incorrectly because of a composition error. The correct table is given on the following page.
Baseline and posttreatment nerve function test values
| Parameter . | Placebo . | Fidarestat . | Difference (95% CI) . | P† . |
|---|---|---|---|---|
| MNCV in median | ||||
| n | 95 | 86 | ||
| Baseline (m/s) | 51.4 ± 0.5 | 51.8 ± 0.4 | ||
| End of treatment (m/s) | 51.2 ± 0.5 | 51.8 ± 0.4 | ||
| Difference (m/s) | −0.2 ± 0.4 | −0.0 ± 0.4 | 0.2 (−0.8 to 1.2) | 0.74 |
| 95% CI | (−0.9 to 0.5) | (−0.8 to 0.7) | ||
| P* | 0.55 | 0.90 | ||
| F wave minimum latency in median | ||||
| n | 96 | 88 | ||
| Baseline (ms) | 31.3 ± 0.3 | 31.3 ± 0.3 | ||
| End of treatment (ms) | 31.6 ± 0.3 | 30.8 ± 0.3 | ||
| Difference (ms) | 0.3 ± 0.2 | −0.5 ± 0.2 | 0.8 (−1.2 to −0.3) | <0.001 |
| 95% CI | (−0.1 to 0.6) | (−0.8 to −0.2) | ||
| P* | 0.11 | <0.01 | ||
| FCV in median | ||||
| n | 96 | 88 | ||
| Baseline (m/s) | 56.7 ± 0.4 | 56.7 ± 0.5 | ||
| End of treatment (m/s) | 56.1 ± 0.4 | 57.6 ± 0.5 | ||
| Difference (m/s) | −0.6 ± 0.3 | 0.9 ± 0.3 | 1.6 (0.8 to 2.4) | <0.001 |
| 95% CI | (−1.2 to −0.1) | (0.3 to 1.5) | ||
| P* | <0.05 | <0.01 | ||
| MNCV in tibial | ||||
| n | 95 | 81 | ||
| Baseline (m/s) | 40.2 ± 0.5 | 40.1 ± 0.4 | ||
| End of treatment (m/s) | 40.3 ± 0.5 | 40.8 ± 0.4 | ||
| Difference (m/s) | 0.1 ± 0.4 | 0.8 ± 0.3 | 0.7 (−0.3 to 1.6) | 0.15 |
| 95% CI | (−0.6 to 0.8) | (0.2 to 1.3) | ||
| P* | 0.81 | <0.01 | ||
| F wave minimum latency in tibial | ||||
| n | 99 | 86 | ||
| Baseline (ms) | 54.8 ± 0.5 | 56.0 ± 0.6 | ||
| End of treatment (ms) | 54.4 ± 0.6 | 55.1 ± 0.6 | ||
| Difference (ms) | −0.4 ± 0.3 | −0.9 ± 0.3 | −0.5 (−1.3 to 0.4) | 0.31 |
| 95% CI | (−1.0 to 0.2) | (−1.5 to −0.2) | ||
| P* | 0.21 | <0.05 | ||
| FCV in tibial | ||||
| n | 99 | 86 | ||
| Baseline (m/s) | 47.7 ± 0.4 | 47.0 ± 0.5 | ||
| End of treatment (m/s) | 48.1 ± 0.5 | 47.6 ± 0.5 | ||
| Difference (m/s) | 0.4 ± 0.3 | 0.6 ± 0.3 | 0.2 (−0.6 to 1.0) | 0.63 |
| 95% CI | (−0.2 to 1.0) | (0.1 to 1.1) | ||
| P* | 0.19 | <0.05 | ||
| SNCV in median (distal) | ||||
| n | 82 | 67 | ||
| Baseline (m/s) | 47.8 ± 0.8 | 48.5 ± 0.9 | ||
| End of treatment (m/s) | 47.6 ± 0.9 | 48.8 ± 0.8 | ||
| Difference (m/s) | −0.1 ± 0.5 | 0.3 ± 0.5 | 0.4 (−1.0 to 1.9) | 0.55 |
| 95% CI | (−1.2 to 0.9) | (−0.7 to 1.3) | ||
| P* | 0.81 | 0.54 | ||
| SNCV in median (forearm) | ||||
| n | 86 | 76 | ||
| Baseline (m/s) | 57.4 ± 0.6 | 57.0 ± 0.7 | ||
| End of treatment (m/s) | 57.4 ± 0.6 | 57.6 ± 0.6 | ||
| Difference (m/s) | −0.0 ± 0.5 | 0.6 ± 0.5 | 0.6 (−0.8 to 2.0) | 0.37 |
| 95% CI | (−1.1 to 1.0) | (−0.3 to 1.5) | ||
| P* | 0.93 | 0.21 |
| Parameter . | Placebo . | Fidarestat . | Difference (95% CI) . | P† . |
|---|---|---|---|---|
| MNCV in median | ||||
| n | 95 | 86 | ||
| Baseline (m/s) | 51.4 ± 0.5 | 51.8 ± 0.4 | ||
| End of treatment (m/s) | 51.2 ± 0.5 | 51.8 ± 0.4 | ||
| Difference (m/s) | −0.2 ± 0.4 | −0.0 ± 0.4 | 0.2 (−0.8 to 1.2) | 0.74 |
| 95% CI | (−0.9 to 0.5) | (−0.8 to 0.7) | ||
| P* | 0.55 | 0.90 | ||
| F wave minimum latency in median | ||||
| n | 96 | 88 | ||
| Baseline (ms) | 31.3 ± 0.3 | 31.3 ± 0.3 | ||
| End of treatment (ms) | 31.6 ± 0.3 | 30.8 ± 0.3 | ||
| Difference (ms) | 0.3 ± 0.2 | −0.5 ± 0.2 | 0.8 (−1.2 to −0.3) | <0.001 |
| 95% CI | (−0.1 to 0.6) | (−0.8 to −0.2) | ||
| P* | 0.11 | <0.01 | ||
| FCV in median | ||||
| n | 96 | 88 | ||
| Baseline (m/s) | 56.7 ± 0.4 | 56.7 ± 0.5 | ||
| End of treatment (m/s) | 56.1 ± 0.4 | 57.6 ± 0.5 | ||
| Difference (m/s) | −0.6 ± 0.3 | 0.9 ± 0.3 | 1.6 (0.8 to 2.4) | <0.001 |
| 95% CI | (−1.2 to −0.1) | (0.3 to 1.5) | ||
| P* | <0.05 | <0.01 | ||
| MNCV in tibial | ||||
| n | 95 | 81 | ||
| Baseline (m/s) | 40.2 ± 0.5 | 40.1 ± 0.4 | ||
| End of treatment (m/s) | 40.3 ± 0.5 | 40.8 ± 0.4 | ||
| Difference (m/s) | 0.1 ± 0.4 | 0.8 ± 0.3 | 0.7 (−0.3 to 1.6) | 0.15 |
| 95% CI | (−0.6 to 0.8) | (0.2 to 1.3) | ||
| P* | 0.81 | <0.01 | ||
| F wave minimum latency in tibial | ||||
| n | 99 | 86 | ||
| Baseline (ms) | 54.8 ± 0.5 | 56.0 ± 0.6 | ||
| End of treatment (ms) | 54.4 ± 0.6 | 55.1 ± 0.6 | ||
| Difference (ms) | −0.4 ± 0.3 | −0.9 ± 0.3 | −0.5 (−1.3 to 0.4) | 0.31 |
| 95% CI | (−1.0 to 0.2) | (−1.5 to −0.2) | ||
| P* | 0.21 | <0.05 | ||
| FCV in tibial | ||||
| n | 99 | 86 | ||
| Baseline (m/s) | 47.7 ± 0.4 | 47.0 ± 0.5 | ||
| End of treatment (m/s) | 48.1 ± 0.5 | 47.6 ± 0.5 | ||
| Difference (m/s) | 0.4 ± 0.3 | 0.6 ± 0.3 | 0.2 (−0.6 to 1.0) | 0.63 |
| 95% CI | (−0.2 to 1.0) | (0.1 to 1.1) | ||
| P* | 0.19 | <0.05 | ||
| SNCV in median (distal) | ||||
| n | 82 | 67 | ||
| Baseline (m/s) | 47.8 ± 0.8 | 48.5 ± 0.9 | ||
| End of treatment (m/s) | 47.6 ± 0.9 | 48.8 ± 0.8 | ||
| Difference (m/s) | −0.1 ± 0.5 | 0.3 ± 0.5 | 0.4 (−1.0 to 1.9) | 0.55 |
| 95% CI | (−1.2 to 0.9) | (−0.7 to 1.3) | ||
| P* | 0.81 | 0.54 | ||
| SNCV in median (forearm) | ||||
| n | 86 | 76 | ||
| Baseline (m/s) | 57.4 ± 0.6 | 57.0 ± 0.7 | ||
| End of treatment (m/s) | 57.4 ± 0.6 | 57.6 ± 0.6 | ||
| Difference (m/s) | −0.0 ± 0.5 | 0.6 ± 0.5 | 0.6 (−0.8 to 2.0) | 0.37 |
| 95% CI | (−1.1 to 1.0) | (−0.3 to 1.5) | ||
| P* | 0.93 | 0.21 |
Data are means ± SEM unless otherwise indicated.
P is the result of one-sample paired t-test within-group comparisons between baseline and posttreatment values, and
P is the result of two-sample t-test comparison between groups.
